Comparison · NCT00480025-sae
GSK1572932 Group vs Placebo Group: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GSK1572932 Group vs Placebo Group: serious adverse events. Trial comparisons, record NCT00480025-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00480025-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.218 | 0.198 | 0.239 | wilson | |
| Risk in group 2 | 0.217 | 0.189 | 0.247 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00118 | -0.0355 | 0.0364 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.852 | 1.19 | log | |
| Odds ratio, group 1 over group 2 | 1.01 | 0.815 | 1.24 | log | |
| Number needed to harm, for one more participant with a serious adverse event on GSK1572932 Group than on Placebo Group | 850 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GSK1572932 Group | Patients received up to 13 doses of GSK1572932, 5 doses every 3 weeks followed by 8 doses every 12 weeks. | 330 | 1,515 | EG000 |
| Group 2 | Placebo Group | Patients received up to 13 doses of placebo, 5 doses every 3 weeks followed by 8 doses every 12 weeks. | 164 | 757 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From screening (Day 0) up to data lock point (DLP) on 23 January 2014, for up to 5 years per patient.
Source ClinicalTrials.gov
Trial
- Title
- GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
- NCT number
- NCT00480025
- Phases
- PHASE3
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- GSK1572932A Antigen-Specific Cancer Immunotherapeutic, Placebo Control
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2019-01-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00480025?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00480025-sae